A population pharmacokinetic meta‐analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects

• Published in: British journal of clinical pharmacology Vol. 83; no. 9; pp. 1932 - 1943
• Main Authors: Edwards, Alena Y., Elgart, Anna, Farrell, Colm, Barnett‐Griness, Ofra, Rabinovich‐Guilatt, Laura, Spiegelstein, Ofer
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01.09.2017
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; antisense oligonucleotide; Clinical Trials as Topic - statistics & numerical data; clusterin; Custirsen; Dose-Response Relationship, Drug; Female; Healthy Volunteers; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms - blood; Nonlinear Dynamics; Oligonucleotides, Antisense - administration & dosage; Oligonucleotides, Antisense - blood; Oligonucleotides, Antisense - pharmacokinetics; Pharmacokinetics; population pharmacokinetics; Thionucleotides - administration & dosage; Thionucleotides - blood; Thionucleotides - pharmacokinetics; Young Adult; clusterin; antisense oligonucleotide; Custirsen; population pharmacokinetics

Aims Custirsen (OGX‐011/TV‐1011), a second‐generation antisense oligonucleotide that reduces clusterin production, is under investigation with chemotherapy in prostate and lung cancer. This meta‐analysis evaluated the population pharmacokinetics (PK) of custirsen in cancer patients and healthy subje...